Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations.

Poor solubility remains a major challenge for pharmaceutical industry, which is now considered to be an area of prime importance in the field of biomedical research. Approximately 40% new molecular entities (NMEs) synthesized in pharmaceutical R with advanced combinatorial chemistry and computer aided drug designing (CADD) approaches suffer from poor solubility and bioavailability related issues. Apart from these presence of intestinal tight junctional epithelial cells, transporters and enzymatic barriers further reduces the oral absorption of drugs.